# US 2025/0017960 A1 · Composition and method of valency controlled receptor systems for cell engineering and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017960 A1
- Document ID: US20250017960A1
- Status: Published application
- Kind: A1
- Application number: 18/704,007
- Filed: 2022-11-15
- Published: 2025-01-16
- Earliest claimed: 2021-11-15
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Lei S. Qi; Paul B. Finn
- Web page: https://patentgrep.com/patent/US20250017960A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/10: characterized by the structure of the chimeric antigen receptor [CAR]
- A61K 2239/13: Antibody-based
- A61K 2239/15: Non-antibody based
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/70: containing domain for protein-protein interaction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are valency controllable receptor polypeptides configured to oligomerize upon recognition of a custom input. The receptors include an extramembrane signal recognition domain configured to recognize an extramembrane signal different from the custom input, a valency control module configured to recognize the custom input and induce oligomerization of the polypeptide, and an intramembrane signaling domain configured to modulate one or more intramembrane pathways. The provided receptors are particularly useful for engineered cell therapies. Also provided are systems and host cells including the disclosed receptors, and methods for using the disclosed materials.

## Claims

### Claim 1

A valency controllable receptor polypeptide comprising:
an extramembrane signal recognition domain having an ability to recognize an extramembrane signal;
a valency controller module comprising:
a controller domain connected to the extramembrane signal recognition domain, wherein the controller domain is configured to recognize a custom input different from the extramembrane signal; and
a transmembrane domain connected to the controller domain;
wherein the valency controller module is configured to oligomerize the valency controllable receptor polypeptide upon recognition of the custom input by the controller domain; and
one or more intramembrane signaling domains connected to the transmembrane domain.

### Claim 2 (depends on 1)

The valency controllable receptor polypeptide of claim 1, wherein the valency controller module further comprises:
one or more linker units connecting the one or more controller domains to the extramembrane domain.

### Claim 3 (depends on 1, 2)

The valency controllable receptor polypeptide of claim 1 or 2, wherein the valency controllable module further comprises:
one or more hinge domains connecting the one or more controller domains to the transmembrane domain.

### Claim 4 (depends on 1, 2, 3)

The valency controllable receptor polypeptide of any one of claims 1-3, wherein the one or more intramembrane signaling domains each independently modulate one or more intramembrane pathways.

### Claim 5 (depends on 4)

The valency controllable receptor polypeptide of claim 4, wherein at least one of the intramembrane signaling domains activates one or more intramembrane pathways.

### Claim 6 (depends on 4, 5)

The valency controllable receptor polypeptide of claim 4 or 5, wherein at least one of the intramembrane signaling domains inhibits one or more intramembrane pathways.

### Claim 7 (depends on 4, 5, 6)

The valency controllable receptor polypeptide of any one of claims 4-6, wherein at least one of the intramembrane signaling domains enhances one or more intramembrane pathways.

### Claim 8 (depends on 4, 5, 6, 7)

The valency controllable receptor polypeptide of any one of claims 4-7, wherein at least one of the one or more intramembrane pathways is an endogenous pathway.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The valency controllable receptor polypeptide of any one of claims 4-8, wherein at least one of the one or more intramembrane pathways is an exogenous pathway.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The valency controllable receptor polypeptide of any one of claims 4-9, wherein at least one of the one or more intramembrane pathways is a synthetic pathway.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The valency controllable receptor polypeptide of any one of claims 4-10, wherein the one or more intramembrane pathways comprise genome sequence editing, transcription activation or repression, epigenetic modifications, genome translocation and rearrangement, RNA expression or degradation, RNA splicing or processing, post-transcription modifications of mRNA or ncRNA, post-translational modifications of proteins, cleavage or proteolysis of proteins, production or degradation of metabolites or other chemistries, antigen recognition or binding, trafficking of signaling molecules, cell cycle control, cell differentiation or reprogramming, T cell activation or exhaustion, programmed cell death, cell trafficking, secretion of cytokines or hormones, neuronal activity, macrophage phagocytosis, neutrophil NETpoptosis, immunological synapse formation, myeloid cell degranulation, antigen presentation, secretion or hypermutation of antibodies, production of oncolytic virus, or a combination thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The valency controllable receptor polypeptide of any one of claims 1-11, wherein the custom input is an extramembrane input.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The valency controllable receptor polypeptide of any one of claims 1-11, wherein the custom input is an intramembrane input.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The valency controllable receptor polypeptide of any one of claims 1-13, wherein the custom input is a valency control ligand.

### Claim 15 (depends on 14)

The valency controllable receptor polypeptide of claim 14, wherein the valency control ligand comprises a small molecule drug.

### Claim 16 (depends on 14, 15)

The valency controllable receptor polypeptide of claim 14 or 15, wherein the valency control ligand comprises a metabolite.

### Claim 17 (depends on 14, 15, 16)

The valency controllable receptor polypeptide of any one of claims 14-16, wherein the valency control ligand comprises an oligonucleotide.

### Claim 18 (depends on 14, 15, 16, 17)

The valency controllable receptor polypeptide of any one of claims 14-17, wherein the valency control ligand comprises a peptide, a protein, a polysaccharide, a lipid, a glycoprotein, or a combination thereof.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The valency controllable receptor polypeptide of any one of claims 14-18, wherein the valency control ligand comprises an antibody, a nanobody, an scFv, a hormone, or a cytokine.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The valency controllable receptor polypeptide of any one of claims 14-19, wherein the valency control ligand comprises a polymer scaffold to which one or more interaction moieties are conjugated, wherein each of the one or more interaction moieties is independently a small molecule, a peptide, an oligonucleotide, a polysaccharide, or a lipid.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The valency controllable receptor polypeptide of any one of claims 1-13, wherein the custom input comprises a change in temperature or pH.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The valency controllable receptor polypeptide of any one of claims 1-13, wherein the custom input comprises a change in sound or electromagnetic radiation.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The valency controllable receptor polypeptide of any one of claims 1-13, wherein the custom input comprises a change in mechanical force.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The valency controllable receptor polypeptide of any one of claims 1-23, wherein the extramembrane signal recognition domain comprises a soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP) receptor domain, a biotin-binding domain, a leucine zipper domain, a single-chain variable fragment (scFv) domain, a nanobody domain, a cell-targeting domain from a natural polypeptide, or a variant or fragment thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The valency controllable receptor polypeptide of any one of claims 1-24, wherein the controller domain comprises a small molecule binding domain.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The valency controllable receptor polypeptide of any one of claims 1-24, wherein the controller domain comprises an FK506 binding protein (FKBP) family domain, a bromodomain and extra terminal domain (BET) family domain, a gibberellin-insensitive dwarf (GID) family domain, a B-cell lymphoma 2 (Bcl-2) family domain, a soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP) receptor domain a biotin-binding domain, a nanobody, a single-chain variable fragment (scFv) domain, an E3 ubiquitin ligase domain, a natural or synthetic peptide epitope, or a variant or fragment thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The valency controllable receptor polypeptide of any one of claims 1-26, wherein the one or more intramembrane signaling domains comprise a CD3ζ (CD247) domain.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The valency controllable receptor polypeptide of any one of claims 1-27, wherein the one or more intramembrane signaling domains comprise an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 29 (depends on 28)

The valency controllable receptor polypeptide of claim 28, wherein the ITAM comprises a sequence from a CD37 domain, from a CD3S domain, from a CD3eε domain, from a DAP12 domain, from a CD32A domain, from a CD32C domain, from a CD132 domain, from a CD79a domain, from a CD79b domain, or from an FCER1G domain.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The valency controllable receptor polypeptide of any one of claims 1-29, wherein the one or more intramembrane signaling domains comprise a CD28 domain, a 4-1BB domain, an OX40 (CD134) domain, an ICOS (CD278) domain, a CD40 domain, a CD2 domain, or a CD27 domain.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A valency controllable receptor system comprising:
two or more valency controllable receptor polypeptides, each independently a valency controllable receptor polypeptide of any one of claims 1-30.

### Claim 32 (depends on 31)

The valency controllable receptor system of claim 31, wherein the amino acid sequence of each of the two or more valency controllable receptor polypeptides is identical.

### Claim 33 (depends on 31)

The valency controllable receptor system of claim 31, wherein the amino acid sequence of a first valency controllable receptor polypeptide of the two or more valency controllable receptor polypeptides differs from the amino acid sequence of a second valency controllable receptor polypeptide of the two or more valency controllable receptor polypeptides.

### Claim 34 (depends on 33)

The valency controllable receptor system of claim 33, wherein at least one of the one or more intramembrane signaling domains of the first valency controllable receptor polypeptide differs from at least one of the one or more intramembrane signaling domains of the second valency controllable receptor polypeptide.

### Claim 35 (depends on 33, 34)

The valency controllable receptor system of claim 33 or 34, wherein the first valency controllable receptor polypeptide comprises a first controller domain configured to recognize a first custom input, and wherein the second valency controllable receptor polypeptide comprises a second controller domain configured to recognize a second custom input different from the first custom input.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The valency controllable receptor system of any one of claims 31-35, further comprising:
a membrane, wherein the transmembrane domain of each of the two or more valency controllable receptor polypeptides is located within the membrane.

### Claim 37 (depends on 36)

The valency controllable receptor system of claim 36, wherein the membrane is a cellular membrane, a nuclear membrane, an organelle membrane, or a vesicle membrane.

### Claim 38 (depends on 31, 32, 33, 34, 35, 36, 37)

The valency controllable receptor system of any one of claims 31-37, further comprising:
a valency control ligand, wherein the valency control ligand is the custom input recognized by the control domain of at least one of the one or more valency control polypeptides.

### Claim 39 (depends on 31, 32, 33, 34, 35, 36, 37, 38)

The valency controllable receptor system of any one of claims 31-38, further comprising:
an antigen, wherein the antigen is the extramembrane signal recognized by the extramembrane signal recognition domain of the one or more valency control polypeptides.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A valency controllable receptor system comprising:
a first valency controllable receptor polypeptides, wherein the first valency controllable receptor polypeptide is a valency controllable receptor polypeptide of any one of claims 1-30; and
a second valency controllable receptor polypeptide comprising:
a second valency controller module comprising:
a second controller domain configured to recognize a second custom input different from the extramembrane signal; and
a second transmembrane domain connected to the second controller domain:
wherein the second valency controller module is configured to oligomerize the second valency controllable receptor polypeptide upon recognition of the second custom input by the second controller domain; and
one or more intramembrane signaling domains connected to the second transmembrane domain.

### Claim 41 (depends on 40)

The valency controllable receptor system of claim 40, wherein the second valency controllable receptor polypeptide does not comprise an extramembrane signal recognition domain having an ability to recognize an extramembrane signal different from the second custom input.

### Claim 42 (depends on 40, 41)

The valency controllable receptor system of claim 40 or 41, wherein the second valency controllable module is configured to oligomerize the first valency controllable receptor polypeptide with the second valency controllable receptor polypeptide upon recognition of the second custom input.

### Claim 43 (depends on 40, 41, 42)

The valency controllable receptor system of any one of claims 40-42, wherein the second custom input is the same as the custom input recognized by the valency controller module of the first valency controllable receptor polypeptide.

### Claim 44 (depends on 43)

The valency controllable receptor system of claim 43, wherein the amino acid sequence of the second valency controller module is the same as the amino acid sequence of the valency controller module of the first valency controllable receptor polypeptide.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The valency controllable receptor system of any one of claims 40-44, wherein at least one of the one or more intramembrane signaling domains of the second valency controllable receptor polypeptide differs from at least one of the one or more intramembrane signaling domains of first valency controllable receptor polypeptide.

### Claim 46 (depends on 40, 41, 42, 43, 44, 45)

The valency controllable receptor system of any one of claims 40-45, further comprising:
a membrane, wherein the second transmembrane domain and the transmembrane domain of the first valency controllable receptor polypeptides are located within the membrane.

### Claim 47 (depends on 46)

The valency controllable receptor system of claim 46, wherein the membrane is a cellular membrane, a nuclear membrane, an organelle membrane, or a vesicle membrane.

### Claim 48 (depends on 40, 41, 42, 43, 44, 45, 46, 47)

The valency controllable receptor system of any one of claims 40-47, further comprising:
a valency control ligand, wherein the valency control ligand is the custom input recognized by the second valency control domain or the valency control domain of the first valency controllable receptor polypeptide.

### Claim 49 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48)

The valency controllable receptor system of any one of claims 40-48, further comprising:
an antigen, wherein the antigen is the extramembrane signal recognized by the extramembrane signal recognition domain of the first valency controllable receptor polypeptide.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A host cell comprising the valency controllable receptor polypeptide of any one of claims 1-30, or the valency controllable receptor system of any one of claims 31-49.

### Claim 51 (depends on 50)

The host cell of claim 50, wherein the host cell is a lymphocyte, a phagocytic cell, a granulocytic cell, or a dendritic cell.

### Claim 52 (depends on 51)

The host cell of claim 51, wherein the lymphocyte is a T cell, a B cell, a natural killer (NK) cell, or an innate lymphoid cell (ILC).

### Claim 53 (depends on 52)

The host cell of claim 52, wherein the T cell is a CD4+ helper αβT cell, a CD8+ killer αβT cell, a δγT cell, or a natural killer T (NKT) cell.

### Claim 54 (depends on 51)

The host cell of claim 51, wherein the phagocytic cell is a monocyte or a macrophage.

### Claim 55 (depends on 51)

The host cell of claim 51, wherein the granulocytic cell is a neutrophil, a basophil, an eosinophil, or a mast cell.

### Claim 56 (depends on 50)

The host cell of claim 50, wherein the host cell is a stem cell or a progenitor cell.

### Claim 57 (depends on 56)

The host cell of claim 56, wherein the stem cell is an induced pluripotent stem cell (iPSC), an embryonic stem cell (ESC), an adult stem cell, or a mesenchymal stem cell (MSC).

### Claim 58 (depends on 56)

The host cell of claim 56, wherein the progenitor cell is a neural progenitor cell, a skeletal progenitor cell, a muscle progenitor cell, a fat progenitor cell, a heart progenitor cell, a chondrocyte, a fibroblast cell, or a pancreatic progenitor cell.

### Claim 59 (depends on 50)

The host cell of claim 50, wherein the host cell is a progenitor-cell-differentiated cell, a stem-cell-differentiated cell, an organoid, or an assembloid.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A method for modulating an intramembrane pathway, the method comprising providing the valency controllable receptor polypeptide of any one of claims 1-30, or the valency controllable receptor system of any one of claims 31-49.

### Claim 61 (depends on 60)

The method of claim 60, further comprising exposing the valency controllable receptor polypeptide to the custom input.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A method for preventing or treating a disease in a subject, the method comprising administering to the subject an amount of the valency controllable receptor polypeptide of any one of claims 1-30, the valency controllable receptor system of any one of claims 31-49 or the host cell of any one of claims 50-59.

### Claim 63 (depends on 62)

The method of claim 62, further comprising, subsequent to the administering, exposing the valency controllable receptor polypeptide to the custom input.

### Claim 64 (depends on 63)

The method of claim 63, wherein the exposing comprises introducing to the subject a therapeutically effective amount of the custom input.

### Claim 65 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is a cancer.

### Claim 66 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is a cancerous tumor.

### Claim 67 (depends on 66)

The method of claim 66, wherein the cancerous tumor is a solid cancerous tumor.

### Claim 68 (depends on 66)

The method of claim 66, wherein the cancerous tumor is a liquid cancerous tumor.

### Claim 69 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is an infectious disease.

### Claim 70 (depends on 69)

The method of claim 69, wherein the infectious disease is a viral infectious disease or a bacterial infectious disease.

### Claim 71 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is an autoimmune disease.

### Claim 72 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is an age-related disease.

### Claim 73 (depends on 62, 63, 64)

The method of any one of claims 62-64, wherein the disease is a neurological disease.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A method for healing a wound in a subject, the method comprising administering to the subject an amount of the valency controllable receptor polypeptide of any one of claims 1-30, or the valency controllable receptor system of any one of claims 31-49, or the host cell of any one of claims 50-59.

### Claim 75 (depends on 74)

The method of claim 74, further comprising, subsequent to the administering, exposing the valency controllable receptor polypeptide to the custom input.

### Claim 76 (depends on 75)

The method of claim 75, wherein the exposing comprises introducing to the subject a therapeutically effective amount of the custom input.
